Breast Cancer

Parul Barry, MD, discusses advances such as ultrahypofractionated radiation and the growing role of AI in streamlining workflows for breast cancer care.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Ifeoma Dikeocha, PhD, discussed how metabolic restriction and fasting-mimicking diets can help optimize chemotherapy outcomes in breast cancer.

A PDUFA date in the second quarter of 2026 has been set for Dato-DXd in patients with unresectable or metastatic TNBC.

In the PATINA trial, adding palbociclib to maintenance therapy significantly improved progression-free survival in patients with HR+, HER2+ breast cancer.

Results of 9 patients with metastatic breast cancer dosed with Bria-IMT have shown sustained survival.

The FDA held a Type B meeting regarding the use of d3-T, a form of testosterone, and the risk of developing breast cancer in women.

Paxalisib combined with pembrolizumab and chemotherapy showed preliminary activity in patients with metastatic triple-negative breast cancer.

The BC-RADS-2 study aimed to address diagnostic delays and cancer care disparities of patients with breast cancer in low- and middle-income countries.

Soumen Das, MBBS, MS, FACS, discussed the BC-RADS-2 study and its potential to transform early breast cancer detection in low- and middle-income countries.

In the ASCENT-04/KEYNOTE-D19 trial, sacituzumab govitecan plus pembrolizumab significantly extended PFS in patients with first-line metastatic TNBC.

The FDA accepted the NDA for gedatolisib for HR+/HER2–, PIK3CA wild-type advanced breast cancer after it reduced the risk of disease progression or death.

The marketing authorization was based on results from the DESTINY-Breast09 trial assessing T-DXd/pertuzumab in first-line HER2+ metastatic breast cancer.

Investigators used the NCCN Distress Thermometer to identify psychological distress in Nigerian patients with breast cancer in a cross-sectional study.

Experts from VCU Massey Cancer Center discuss seamlessly integrating bioimpedance spectroscopy into standard workflows for lymphedema detection.

Researchers highlight the importance of geriatric assessments and patient-centered outcomes to manage unique physiological and functional challenges in older breast cancer survivors.

Previously, the phase 2 EVANGELINE trial assessed treatment with (Z)-endoxifen in this patient group.

Nurses preferred the FreedomEDGE infusion system compared with the manual push technique in a retrospective survey study.

VCU Massey Cancer Center is utilizing L-Dex bioimpedance spectroscopy to move toward a preventative model for lymphedema.

Frequent follow-up to determine if lymphedema has developed is necessary to catch it early and begin rehabilitation processes.

The use of bioimpedance spectroscopy takes under 2 minutes and can help detect lymphedema before symptoms appear.

Data from a phase 2 study may support a novel mTOR inhibitor-based regimen in previously treated, HR-positive, HER2-negative breast cancer.

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Kandance P. McGuire, MD, FACS, breaks down what lymphedema is and why it may be detected later.